Amarantus Diagnostics Announces Acceptance of Two Late-Breaking Abstracts on LymPro Test(R) Data at the 2015 Alzheimer's Asso...
June 09 2015 - 10:58AM
Amarantus Diagnostics, a neurology-focused diagnostics company
developing diagnostic tests for Multiple Sclerosis and Alzheimer's
disease, announced two late-breaking abstracts on the LymPro Test®
have been accepted for presentation at the Alzheimer's Association
International Conference® (AAIC) being held July 18-23, 2015, in
Washington, DC. Amarantus Diagnostics, Inc. is a Silver Sponsor of
the 2015 AAIC. Amarantus Diagnostics is a wholly-owned subsidiary
of Amarantus Bioscience Holdings (OTCQB:AMBS).
Amarantus Diagnostics will present data from two studies on its
LymPro blood-based diagnostic assay for Alzheimer's disease (AD)
during AAIC poster sessions in abstracts entitled:
"The LymPro Test®: A Biomarker for Alzheimer's Disease Using
Blood Samples from Clinically Diagnosed Alzheimer's Disease and
Cognitively Intact Subjects."
"The LymPro Test®: A Fit for Purpose Validation of a Flow
Cytometric Assay to Assess Lymphocyte Proliferation in Peripheral
Blood Lymphocytes in Alzheimer's Disease."
The LymPro Test measures lymphocyte proliferation in response to
a mitogenic stimulus and quantifies the extent to which lymphocytes
have entered the cell division cycle. Cell cycle dysregulation in
neurons is a key pathology in AD, that results in neuronal death
and cognitive decline. In the LymPro Test, lymphocyte measurements
are used as a surrogate for this neuronal cell dysfunction.
About AAIC
The Alzheimer's Association International Conference® (AAIC) is
the world's largest forum for the dementia research community.
International investigators, clinicians and care providers gather
annually to share the latest study results, theories and
discoveries to bring the world closer to breakthroughs in dementia
science. As part of the Alzheimer's Association's research program,
AAIC serves as a catalyst for generating new knowledge about
dementia and fostering a vital, collegial research community.
About Alzheimer's Disease
According to the Alzheimer's Association, it is estimated that
over 5.4 million people in the United States suffer from
Alzheimer's disease. Over 500,000 patients are diagnosed annually,
with nearly one-in-eight older Americans affected by the disease.
Alzheimer's disease is the third leading cause of death in the
United States. The cost of unpaid care in the United States is
estimated at over $210 billion annually. Total payments for care
are estimated at over $200 billion annually, including $140 billion
in cost to Medicare and Medicaid. Alzheimer's expenditures in the
United States are expected to exceed $1.2 trillion by 2050. There
is no cure or effective treatment for Alzheimer's disease.
Worldwide, about 35.6 million individuals have the disease and,
according to the World Health Organization, the number will double
every 20 years to 115.4 million people with Alzheimer's by
2050.
About LymPro Test®
The Lymphocyte Proliferation Test (LymPro Test®) is a diagnostic
blood test that determines the ability of peripheral blood
lymphocytes to withstand an exogenous mitogenic stimulation that
induces them to enter the cell cycle. It is believed that certain
diseases, most notably Alzheimer's disease, are the result of
compromised cellular machinery that leads to aberrant cell cycle
re-entry by neurons. LymPro is unique in the use of peripheral
blood lymphocytes (PBLs) as a surrogate for neuronal cell function,
suggesting a common immune-based relationship between PBLs and
neurons in the brain.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company
developing treatments and diagnostics for diseases in the areas of
neurology, psychiatry, ophthalmology and regenerative medicine.
AMBS' Therapeutics division has development rights to eltoprazine,
a Phase 2b ready small molecule indicated for Parkinson's disease
levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression,
and owns the intellectual property rights to a therapeutic protein
known as mesencephalic-astrocyte-derived neurotrophic factor (MANF)
and is developing MANF-based products as treatments for brain and
ophthalmic disorders. AMBS' Diagnostics division owns the rights to
MSPrecise®, a proprietary next-generation DNA sequencing (NGS)
assay for the identification of patients with relapsing-remitting
multiple sclerosis (RRMS) at first clinical presentation, has an
exclusive worldwide license to the Lymphocyte Proliferation test
(LymPro Test®) for Alzheimer's disease, which was developed by
Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and
owns intellectual property for the diagnosis of Parkinson's disease
(NuroPro). AMBS also owns the discovery of neurotrophic factors
(PhenoGuard™) that led to MANF's discovery.
For further information please visit www.Amarantus.com, or
connect with the Company on Facebook, LinkedIn, Twitter and
Google+.
Forward-Looking Statements
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believes," "project,"
"expects," "anticipates," "estimates," "intends," "strategy,"
"plan," "may," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ
materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies
is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a
consolidated basis include, but are not limited to: changes in
economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be
considered in evaluating forward-looking statements and undue
reliance should not be placed on such statements.
CONTACT: Investor and Media Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T: (US) 908.938.1475
E: jenene@jenenethomascommunications.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2024 to May 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From May 2023 to May 2024